{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T06:01:18Z","timestamp":1783576878181,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.jval.2022.09.010","type":"journal-article","created":{"date-parts":[[2022,11,3]],"date-time":"2022-11-03T18:30:52Z","timestamp":1667500252000},"page":"336-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the \u201cAge of Cures\u201d and Their Implications for Dynamic Efficiency"],"prefix":"10.1016","volume":"26","author":[{"suffix":"Jr.","given":"Louis P.","family":"Garrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boshen","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Dabbous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jval.2022.09.010_bib1","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1377\/hlthaff.23.1.89","article-title":"How much should Medicare pay for drugs?","volume":"23","author":"Newhouse","year":"2004","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"10.1016\/j.jval.2022.09.010_bib2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0272989X04273139","article-title":"Impact of generic drug entry on cost-effectiveness analysis","volume":"25","author":"Shih","year":"2005","journal-title":"Med Decis Making"},{"issue":"1","key":"10.1016\/j.jval.2022.09.010_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/11584230-000000000-00000","article-title":"Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis","volume":"29","author":"Hoyle","year":"2011","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.jval.2022.09.010_bib4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jval.2021.06.014","article-title":"Do cost-effectiveness analyses account for drug genericization? A literature review and assessment of implications","volume":"25","author":"Neumann","year":"2022","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2022.09.010_bib5","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jval.2021.02.008","article-title":"Does cost-effectiveness analysis overvalue potential cures? Exploring alternative methods for applying a \u201cshared savings\u201d approach to cost offsets","volume":"24","author":"Chapman","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2022.09.010_bib6","first-page":"497","article-title":"Bias within economic evaluations \u2013 the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug","volume":"7","author":"Guertin","year":"2015","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.jval.2022.09.010_bib7","author":"Pistollato"},{"issue":"7","key":"10.1016\/j.jval.2022.09.010_bib8","first-page":"793","article-title":"Value-based pricing for emerging gene therapies: the economic case for a higher cost-effectiveness threshold","volume":"25","author":"Garrison","year":"2019","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.jval.2022.09.010_bib9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.healthpol.2021.11.005","article-title":"Amortization of gene replacement therapies: a health policy analysis exploring a mechanism for mitigating budget impact of high-cost treatments","volume":"126","author":"Dabbous","year":"2022","journal-title":"Health Policy"},{"issue":"11","key":"10.1016\/j.jval.2022.09.010_bib11","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1001\/jamainternmed.2017.4329","article-title":"Determinants of market exclusivity for prescription drugs in the United States","volume":"177","author":"Kesselheim","year":"2017","journal-title":"JAMA Intern Med"},{"issue":"3","key":"10.1016\/j.jval.2022.09.010_bib12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s13577-021-00512-4","article-title":"COVID-19 vaccines: rapid development, implications, challenges and future prospects","volume":"34","author":"Kashte","year":"2021","journal-title":"Hum Cell"},{"issue":"suppl 1","key":"10.1016\/j.jval.2022.09.010_bib13","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1634\/theoncologist.2010-S1-49","article-title":"Rewarding value creation to promote innovation in oncology: the importance of considering the global product life cycle","volume":"15","author":"Garrison","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.jval.2022.09.010_bib14","author":"Chapman"},{"key":"10.1016\/j.jval.2022.09.010_bib15","author":"Palnoch"},{"issue":"1","key":"10.1016\/j.jval.2022.09.010_bib16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.clinthera.2019.11.006","article-title":"Implementation of value-based pricing for medicines","volume":"42","author":"Jommi","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.jval.2022.09.010_bib17","first-page":"763","article-title":"Markets for pharmaceutical products","volume":"Vol. 2","author":"Morton","year":"2011"},{"issue":"3","key":"10.1016\/j.jval.2022.09.010_bib19","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/1468-0009.12279","article-title":"Comparing generic drug markets in Europe and the United States: prices, volumes, and spending","volume":"95","author":"Wouters","year":"2017","journal-title":"Milbank Q"},{"issue":"1","key":"10.1016\/j.jval.2022.09.010_bib20","first-page":"171","article-title":"Generic medicine pricing in Europe: current issues and future perspective","volume":"11","author":"Simoens","year":"2008","journal-title":"J\u00a0Med Econ"},{"issue":"5","key":"10.1016\/j.jval.2022.09.010_bib24","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhealeco.2008.05.010","article-title":"Cost-effectiveness analysis and innovation","volume":"27","author":"Jena","year":"2008","journal-title":"J\u00a0Health Econ"},{"key":"10.1016\/j.jval.2022.09.010_bib25","article-title":"The value of innovation under value-based pricing","volume":"4","author":"Moreno","year":"2016","journal-title":"J\u00a0Mark Access Health Policy"},{"key":"10.1016\/j.jval.2022.09.010_bib27","author":"Purvis"},{"issue":"8","key":"10.1016\/j.jval.2022.09.010_bib28","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.13595","article-title":"Characteristics and price increases among sole-source, off-patent drugs in the United States, 2008 to 2018","volume":"3","author":"Alpern","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"6","key":"10.1016\/j.jval.2022.09.010_bib30","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.jval.2019.03.012","article-title":"Analytic considerations in applying a general economic evaluation reference case to gene therapy","volume":"22","author":"Drummond","year":"2019","journal-title":"Value Health"},{"issue":"6","key":"10.1016\/j.jval.2022.09.010_bib31","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1016\/j.jval.2019.03.013","article-title":"Uncertainty and cures: discontinuation, irreversibility, and outcomes-based payments: what is different about a one-off treatment?","volume":"22","author":"Towse","year":"2019","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.jval.2022.09.010_bib32","first-page":"501","article-title":"Assessing the potential cost-effectiveness of a gene therapy for the treatment of hemophilia A","volume":"23","author":"Cook","year":"2020","journal-title":"J\u00a0Med Econ"},{"issue":"5","key":"10.1016\/j.jval.2022.09.010_bib33","first-page":"674","article-title":"Gene therapy may not be as expensive as people think: challenges in assessing the value of single and short-term therapies","volume":"27","author":"Garrison","year":"2021","journal-title":"J\u00a0Manag Care Spec Pharm"},{"issue":"1","key":"10.1016\/j.jval.2022.09.010_bib34","article-title":"Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients","volume":"7","author":"Malone","year":"2019","journal-title":"J\u00a0Mark Access Health Policy"},{"key":"10.1016\/j.jval.2022.09.010_bib35","author":"Kolchinsky","year":"2020"},{"issue":"6","key":"10.1016\/j.jval.2022.09.010_bib36","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jval.2016.03.1859","article-title":"Financing a cure for diabetes in a multipayer environment","volume":"19","author":"Basu","year":"2016","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2022.09.010_bib37","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jval.2017.12.009","article-title":"A\u00a0health economics approach to US value assessment frameworks-summary and recommendations of\u00a0the ISPOR Special Task Force Report [7]","volume":"21","author":"Garrison","year":"2018","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.jval.2022.09.010_bib38","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.jval.2020.10.003","article-title":"Health technology assessment with diminishing returns to health: the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) approach","volume":"24","author":"Lakdawalla","year":"2021","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2022.09.010_bib39","series-title":"Cost-Effectiveness in Health and Medicine","first-page":"xv","article-title":"Second panel on cost-effectiveness in health and medicine","author":"Neumann","year":"2016"},{"issue":"2","key":"10.1016\/j.jval.2022.09.010_bib40","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.healthpol.2011.06.001","article-title":"A\u00a0new prize system for drug innovation","volume":"102","author":"Gandjour","year":"2011","journal-title":"Health Policy"},{"issue":"4","key":"10.1016\/j.jval.2022.09.010_bib41","first-page":"1137","article-title":"Patent buyouts: a mechanism for encouraging innovation","volume":"113","author":"Kremer","year":"1998","journal-title":"Q\u00a0J Econ"},{"issue":"9709","key":"10.1016\/j.jval.2022.09.010_bib42","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0140-6736(09)61296-4","article-title":"The Health Impact Fund: incentives for improving access to medicines","volume":"375","author":"Banerjee","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jval.2022.09.010_bib43","author":"Elijah"},{"issue":"9","key":"10.1016\/j.jval.2022.09.010_bib44","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jval.2022.09.010_bib45","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s40273-018-0696-4","article-title":"Differential pricing of pharmaceuticals: theory, evidence and emerging issues","volume":"36","author":"Danzon","year":"2018","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.jval.2022.09.010_bib46","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.815029","article-title":"Assessing the consequences of external reference pricing for global access to medicines and innovation: economic analysis and policy implications","volume":"13","author":"Incze","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jval.2022.09.010_bib47","author":"Hitch"},{"issue":"7","key":"10.1016\/j.jval.2022.09.010_bib48","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10198-019-01032-7","article-title":"Is rate of return pricing a useful approach when value-based pricing is not appropriate?","volume":"20","author":"Drummond","year":"2019","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2022.09.010_bib49","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s12962-020-00223-x","article-title":"Establishing a reasonable price for an orphan drug","volume":"18","author":"Berdud","year":"2020","journal-title":"Cost Eff Resour Alloc"},{"issue":"9","key":"10.1016\/j.jval.2022.09.010_bib50","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jval.2021.04.1277","article-title":"Reimagining pharmaceutical market exclusivities: should the duration of guaranteed monopoly periods be value based?","volume":"24","author":"Beall","year":"2021","journal-title":"Value Health"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522021891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301522021891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:30:57Z","timestamp":1761096657000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301522021891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1098301522021891"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2022.09.010","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Value-Based Pricing for Patent-Protected Medicines Over the Product Life Cycle: Pricing Anomalies in the \u201cAge of Cures\u201d and Their Implications for Dynamic Efficiency","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2022.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}